CompletedPhase 2NCT05455424
Niraparib Efficacy in Patient With Unresectable Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Principal Investigator
- Dean FennellUniversity of Leicester
- Intervention
- Niraparib Oral Product(drug)
- Enrollment
- 88 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (11)
- University Hospital Southampton, Southampton General Hospital, Southampton, Hampshire, United Kingdom
- Medway NHS Foundation Trust, Medway Maritime Hospital, Gillingham, Kent, United Kingdom
- Somerset NHS Foundation Trust, Musgrove Park Hospital, Taunton, Somerset, United Kingdom
- Belfast Health and Social Care Trust, Belfast City Hospital, Belfast, United Kingdom
- Velindre University NHS Trust, Velindre Cancer Centre, Cardiff, United Kingdom
- Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
- The Princess Alexandra Hospital NHS Trust, The Princess Alexandra Hospital, Harlow, United Kingdom
- Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Hull, United Kingdom
- Leeds Teaching Hospitals NHS Trust, St James's Hospital, Leeds, United Kingdom
- University Hospitals of Leicester NHS Trust, Royal Leicester Infirmary, Leicester, United Kingdom
- Sheffield Teaching Hospitals NHS Foundation Trust, Weston Park Hospital, Sheffield, United Kingdom
Collaborators
University of Southampton · British Lung Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05455424 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited